Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
It was a relatively quiet week for clinical trial announcements. Here’s a look.
Gaithersburg, Maryland-based Arcellx, Inc. unveiled its ticker symbol on the Nasdaq Friday, hitting the market at a cool $15 per share.
After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of its corporate umbrella supporting its three-year-old “Play to Win” strategy.
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
UCB hit the mark in its Phase III clinical trial assessing zilucoplan, while Vanda failed its late-stage study of tradipitant.
Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.
Data from Phase III ECHELON-1 clinical study conducted with either stage III or stage IV cHL showed consistent improvement in OS across each of the six 28-day cycles completed.
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
PRESS RELEASES
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
Highlights TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications LOI includes minimum annual purchase commitments in Year 1 Expands TempraMed’s footprint across the Middle East and supports broader regional commercialization strategy Potential future expansion includes VIVI Med™, VIVI Epi™, and VIVI Cap Smart™ products
— Veteran Physician-Scientist Brings Over 25 Years of Pulmonary and Cardiopulmonary Clinical Development Leadership Spanning Pfizer, Gilead, and Aerovate Therapeutics —